S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
In quiet debut, Alzheimer's drug finds questions, skepticism
Ship owner, operator of interest in California oil spill
Coast Guard: 1,200-foot ship dragged California oil pipeline
AP review: At least 13 auto safety rules are years overdue
4 Traits Every Leadership Team Should Invest In
The Latest: Another record in Russia's daily virus numbers
Face failure and learn from your successes in 7 steps
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
In quiet debut, Alzheimer's drug finds questions, skepticism
Ship owner, operator of interest in California oil spill
Coast Guard: 1,200-foot ship dragged California oil pipeline
AP review: At least 13 auto safety rules are years overdue
4 Traits Every Leadership Team Should Invest In
The Latest: Another record in Russia's daily virus numbers
Face failure and learn from your successes in 7 steps
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
In quiet debut, Alzheimer's drug finds questions, skepticism
Ship owner, operator of interest in California oil spill
Coast Guard: 1,200-foot ship dragged California oil pipeline
AP review: At least 13 auto safety rules are years overdue
4 Traits Every Leadership Team Should Invest In
The Latest: Another record in Russia's daily virus numbers
Face failure and learn from your successes in 7 steps
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
In quiet debut, Alzheimer's drug finds questions, skepticism
Ship owner, operator of interest in California oil spill
Coast Guard: 1,200-foot ship dragged California oil pipeline
AP review: At least 13 auto safety rules are years overdue
4 Traits Every Leadership Team Should Invest In
The Latest: Another record in Russia's daily virus numbers
Face failure and learn from your successes in 7 steps
CVE:IGX

IntelGenx Technologies Stock Forecast, Price & News

C$0.58
+0.01 (+1.75 %)
(As of 10/6/2021)
Add
Compare
Today's Range
C$0.58
▼
C$0.60
50-Day Range
C$0.49
▼
C$0.62
52-Week Range
C$0.17
▼
C$0.85
Volume11,848 shs
Average Volume56,279 shs
Market CapitalizationC$87.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive IGX News and Ratings via Email

Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter.


About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Headlines

IntelGenx Technologies Corp. Virtually Opens the Market
October 12, 2021 |  finance.yahoo.com
Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
October 12, 2021 |  finance.yahoo.com
IntelGenx Announces Market Launch of RIZAPORT® in Spain
September 7, 2021 |  au.finance.yahoo.com
IntelGenx Announces Closing of Notes Offering
August 5, 2021 |  finance.yahoo.com
eLearning Brothers Rocks Compliance with Traliant and Diversified Cutout Collection
July 30, 2021 |  nz.finance.yahoo.com
IntelGenx’s VetaFilm™ Platform to be Evaluated by One of the World’s Fastest Growing Animal Healthcare Companies
June 8, 2021 |  markets.businessinsider.com
IntelGenx Announces Initial Closing of atai Investment
May 14, 2021 |  markets.businessinsider.com
Insiders buying as IntelGenx moves into psychedelics
April 24, 2021 |  theglobeandmail.com
IntelGenx Announces Intention to Amend Convertible Unsecured Promissory Notes
April 9, 2021 |  finance.yahoo.com
IntelGenx Reports Fourth Quarter and Full-Year 2020 Financial Results
March 25, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:IGX
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.intelgenx.com
Phone
514-331-7440
Employees
48
Year Founded
N/A

Sales & Book Value

Annual Sales
C$1.75 million
Price / Sales
49.95
Cash Flow
C$0.08 per share
Price / Cash Flow
7.16
Book Value
C$0.05 per share
Price / Book
12.89

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
164.62
Current Ratio
2.77
Quick Ratio
2.69

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
150,546,000
Market Cap
C$87.32 million
Next Earnings Date
11/10/2021 (Estimated)
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












IntelGenx Technologies (CVE:IGX) Frequently Asked Questions

What stocks does MarketBeat like better than IntelGenx Technologies?

Wall Street analysts have given IntelGenx Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IntelGenx Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is IntelGenx Technologies' next earnings date?

IntelGenx Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for IntelGenx Technologies.

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (CVE:IGX) released its quarterly earnings data on Wednesday, August, 4th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million for the quarter.
View IntelGenx Technologies' earnings history.

How has IntelGenx Technologies' stock price been impacted by COVID-19 (Coronavirus)?

IntelGenx Technologies' stock was trading at C$0.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IGX stock has increased by 7.4% and is now trading at C$0.58.
View which stocks have been most impacted by COVID-19.

Who are IntelGenx Technologies' key executives?

IntelGenx Technologies' management team includes the following people:
  • Dr. Horst G. Zerbe, Chairman, CEO & Chairman of Scientific Advisory Board (Age 74, Pay $240.75k)
  • Mr. André Godin C.A., CPA, CPA, CA, Pres & CFO (Age 57, Pay $223.6k)
  • Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp (Age 44, Pay $140.13k)
  • Dr. Dana Matzen, VP of Bus. & Corp. Devel. of IntelGenx Corp (Age 43, Pay $171.43k)
  • Stephen Kilmer, Investor Relations Officer
  • Dr. Rodolphe Obeid Ph.D., VP of Operations - IntelGenx Corp (Age 41)
  • Mr. Tommy Kenny J.D., L.L.B., M.Sc., VP of Intellectual Property & Legal Affairs and Gen. Counsel of IntelGenx Corp (Age 34)
  • Ms. Ingrid Zerbe, Corp. Sec. (Age 67)

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include IntelGenx Technologies (IGXT), Aurora Cannabis (ACB), New Age Brands (NF), Capstone Mining (CS), Hanesbrands (HBI), Tilray (TLRY), ACADIA Pharmaceuticals (ACAD), AusCann Group (AC8), Cameco (CCJ) and Baylin Technologies (BYL).

What is IntelGenx Technologies' stock symbol?

IntelGenx Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX."

How do I buy shares of IntelGenx Technologies?

Shares of IGX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is IntelGenx Technologies' stock price today?

One share of IGX stock can currently be purchased for approximately C$0.58.

How much money does IntelGenx Technologies make?

IntelGenx Technologies has a market capitalization of C$87.32 million and generates C$1.75 million in revenue each year.

How many employees does IntelGenx Technologies have?

IntelGenx Technologies employs 48 workers across the globe.

What is IntelGenx Technologies' official website?

The official website for IntelGenx Technologies is www.intelgenx.com.

How can I contact IntelGenx Technologies?

The company can be reached via phone at 514-331-7440.


This page was last updated on 10/17/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.